|Day Low/High||72.18 / 74.01|
|52 Wk Low/High||64.27 / 89.54|
These call buyers may have expected positive, bullish news in the coming weeks, on the belief that the pipeline for GILD is broad with a multitude of opportunities to serve as catalysts.
Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision's proprietary genome...
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that FINCH 2, a global, randomized, placebo-controlled, Phase 3 study of filgotinib, an investigational, selective JAK1 inhibitor, in adults with...
Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV (Euronext & NASDAQ:GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint...
Gilead Sciences, Inc. (NASDAQ: GILD) and Trianni, Inc.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F.
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Laura Hamill will join the company as Executive Vice President, Worldwide Commercial Operations, and will become a member of Gilead's senior leadership team.
Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission (EC) has granted Marketing Authorization for Yescarta ® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell...
Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company's medicines and increase focus on reaching patients.
The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Drug Administration (CNDA) has approved Genvoya ® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1...
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2018.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F.
Is the pharma sector fever heating up in 2H18? Drug investors, get ready as there could be some good trades to be made.
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results of a retrospective nationwide analysis of the impact of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) for pre-exposure prophylaxis (PrEP) use across all 50 U.
Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V.
Some beaten up biotech names are finally coming back to life. Here's a look at the technical analysis.
Investors have never gone wrong buying Netflix on the dips. Jim Cramer tells you what to make of the 'FANG Musketeers.'
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes.
Kite, a Gilead Company (NASDAQ: GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
This biotech's weekly chart is very encouraging.
Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company's Marketing Authorization Application (MAA) for Yescarta ®...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.